Direct-Acting Antiviral Hepatitis C Therapy in Patients with Chronic Renal Failure
Abstract: The prevalence of hepatitis C virus (HCV) infection is estimated at 3 % in the global population, it is higher in patients on hemodialysis, the treatment of viral hepatitis C has increased with appearance of new antiviral molecules specifically targeting the virus that has revolutionized the therapeutic response Materials and methods this is a retrospective study from 2015 to February 2018 in the service of hepato-gastroenterology, University Hospital Mohamed VI, Marrakech including 33 hemodialysis patients or follow-up for renal insufficiency not dialyzed and put on treatment by sofosbuvir400mg / day in association with daclatasvir 60mg / d including 2 patients with severe renal insufficiency (creatinine clearance
Keywords: viral hepatitis C, hemodialysis, renal failure, direct antivirals, response, adverse effects
How to Cite?: K. Krati, A. Benayad, Z. Semalni, S. Oubaha, "Direct-Acting Antiviral Hepatitis C Therapy in Patients with Chronic Renal Failure", Volume 7 Issue 6, June 2018, International Journal of Science and Research (IJSR), Pages: 1022-1025, https://www.ijsr.net/getabstract.php?paperid=ART20182944, DOI: https://dx.doi.org/10.21275/ART20182944